Network Insights Methodology Get Access

Pfizer

ORG Health Care / Pharmaceuticals Momentum 16.1ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$58.5B revenue (2025), New York-based Pfizer develops vaccines, oncology, and primary-care medicines. Recent pipeline progress includes next-gen pneumonia vaccine data and VEGF bispecific collaboration announcements at ASCO 2026; concurrent litigation exposure in Europe over vaccine safety claims.

Pfizer-3SBio collaboration on VEGF bispecific therapeutics; pneumonia vaccine program (next-gen shot competing with Prevnar 20); ongoing vaccine and oncology pipeline development.
0.07
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
16.1
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
10
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
Merck Novartis FDA AMD S&P 500 AstraZeneca Nvidia White House Alphabet United Airlines Walmart NYSE CEO Middle East Rocket
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-25 2026-05-25 10 0 Degree Mentions
Signal Decomposition
Attention Cascade
0.236
Narrative Drift
0.000
Spectral Shift
624.046
Sentiment-Momentum Divergence
0.000
Source Concentration
0.846
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
10 Degree Centrality
Ego Network (top connections)
Merck (weight 70.0)Novartis (weight 68.0)FDA (weight 11.0)AMD (weight 3.0)S&P 500 (weight 3.0)AstraZeneca (weight 3.0)Nvidia (weight 2.0)White House (weight 2.0) MerckNovartisFDAAMDS&P 500AstraZenecaNvidiaWhite House Pfizer (degree 10) Pfizer
Centrality History
2026-04-25 2026-05-25 10 0 Degree Mentions
EntityWeight StatusFirst Seen
Merck 70 STRENGTHENED
Novartis 68 STRENGTHENED
FDA 11 STABLE
AMD 3 NEW
S&P 500 3 NEW
AstraZeneca 3 NEW
Nvidia 2 STABLE
White House 2 STABLE
Alphabet 2 STABLE
United Airlines 2 NEW
Walmart 2 NEW
NYSE 2 STABLE
CEO 2 STABLE
Middle East 2 STABLE
Rocket 2 NEW
World Health Organization 1 STABLE
Novo Nordisk 1 NEW
Italy 1 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-25 ← Intelligence Network